Featured News
Lentivation™ Sets a Course for Rapid Gene Therapy Manufacturing
Lentiviral vector platform enables a cost-effective and reliable path to GMP in less than seven months
Leveraging decades of viral vector contract development and manufacturing organization (CDMO) experience, we have established an industry-leading platform that streamlines the pathway to GMP lentiviral vector (LVV) manufacturing.
With a maturing market requiring a secure and standardized approach to clinical and commercial supply, Lentivation™ integrates the three pillars of plasmid DNA, lentiviral vector production, and testing, to provide LVV-based gene therapy and gene-modified cell therapy developers with up to 60% timeline reduction, translating to fewer than seven months, compared to traditional manufacturing workflows.
The addition of this proven platform offering further bolsters our commitment to supporting cell and gene therapy developers, and follows the introduction of off-the-shelf (OTS) LVV packaging and AAV pHelper plasmids, the eXpDNA™ plasmid manufacturing platform, the nAAVigation® AAV vector production platform, and cell therapy New Product Introduction technology transfer framework.
“We are thrilled to add the Lentivation platform to our robust portfolio of existing capabilities,” commented Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, in a press release announcing the platform. “Our LVV manufacturing offerings allow us to further support advanced therapy programs and, most importantly, deliver novel gene therapies to patients across the globe."
Virtual Launch Event
The Lentivation platform was unveiled during a BioInsights hosted roundtable event, Exploring Current and Future Trends in Lentiviral Vector Manufacturing, on September 27, which also featured esteemed speakers from Dark Horse Consulting, Flagship Pioneering, Gamma Biosciences, and Quell Therapeutics.
Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, highlights the key benefits of the platform to gene and gene-modified cell therapy developers:
Speed
Expedited development and 100% in-house analytics
Track Record
Differentiated CDMO and integrated testing powerhouse
Predictability
Cost-effective, reliable path to GMP and clinic
Roundtable: Trends in Lentiviral Vector Manufacturing
Bringing together acknowledged experts in the field of LVV design, manufacture, and regulation, join us to examine key trends and point the way to future success.
Watch On Demand
Beth Tebeau, Site Director at our Rockville, MD, viral vector CDMO center of excellence, also commented on the launch: “Charles River’s LVV platform provides a streamlined, reliable path for therapeutic developers to clinic and commercial… [building on] established capabilities and processes, fine-tuned over decades spent successfully supporting advanced therapy clients.”
For more information on our viral vector development and manufacturing services, including scaled GMP production of lentiviral vector, AAV, adenovirus, and retrovirus, viral vector packaging services, and products, please visit: Cell and Gene Therapy CDMO Solutions.